Medical condition
Renal Cell Carcinoma
Renal Cell Carcinoma is a medical condition tracked by NovaPharmaNews across 11 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- cabozantinib (CABOMETYX) Antineoplastic and immunomodulating agents (L01)
- axitinib (INLYTA) Antineoplastic and immunomodulating agents (L01)
- nivolumab (OPDIVO) Antineoplastic and immunomodulating agents (L01)
- belzutifan (WELIREG) Antineoplastic and immunomodulating agents (L01)
- ipilimumab (YERVOY) Antineoplastic and immunomodulating agents (L01)
- avelumab (BAVENCIO) Antineoplastic and immunomodulating agents (L01)
- pembrolizumab (KEYTRUDA) Antineoplastic and immunomodulating agents (L01)
- sorafenib (NEXAVAR) Antineoplastic and immunomodulating agents (L01)
- lenvatinib (LENVIMA) Antineoplastic and immunomodulating agents (L01)
- sunitinib (ARX-SUNITINIB) Antineoplastic and immunomodulating agents (L01)
- tivozanib hydrochloride monohydrate (FOTIVDA) Antineoplastic and immunomodulating agents (L01)
